IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
No Data found.
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Comparison of efficacy of rosuvastatin as cholesterol synthesis inhibitor with atorvastatin and simvastatin in patients with hypercholesterolemia

Author: BUSHRAMAHMOOD HUSSEIN, SALIH MAHDI SALMAN, ZUHAIRMAROOF HUSSEIN
Abstract: Atherosclerosis complications such as coronary heart disease (CHD ), adversely affect quality of life and still account for considerable numbers of morbidity and mortality in modernized societies. Along with other risk factors, hypercholesterolemia has the main part in the causes of atherosclerosis specially the level of low-density lipoprotein cholesterol (LDL -C ). Studies have showed a continuous and stepwise association between hypercholesterolemia and risk of death from coronary heart disease. Prospective study done during the dated from January 2019 to July 2019. A total of 95 patients, The blood certified to clot for 30 minutes at chamber heat and separated the serum by 3000 rpm centrifugation for 10 minutes and transported into plain plastic tubes and frozen at -20 C until the time of assay of lipid profile parameters (LDL-C, TC, HDL, TG ). patients take rosuvastatin had significant effect (P-value < 0.05 ) on LDL at dose (40 ) mg more than atorvastatin and simvastatin, 32 patients take atorvastatin had more effect on LDL than 31 patients take simvastatin, the same thing on the dose (10 ) mg and (20 ) mg for all 3 drugs. In drug itself there is a significant effect (P-value < 0.05 ) of rosuvastatin, simvastatin and atorvastatin on LDL at dose (40 ) mg more than dose (20 ) mg and (10 ) mg. rosuvastatin after 6 weeks of treatment on all contents of lipid profile the in all 3 doses 10 mg, 20mg and 40mg more significant effect on LDL then on TC. Conclusion: rosuvastatin as cholesterol synthesis inhibitor had more effect on LDL and TC thanatorvastatin and simvastatin. 40 mg is more affected dose of rosuvastatin.
Keyword: rosuvastatin, cholesterol synthesis inhibitor, atorvastatin, simvastatin, hypercholesterolemia
DOI: https://doi.org/10.31838/ijpr/2020.12.01.055
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free